Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 942.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 88,320 shares of the biotechnology company’s stock after purchasing an additional 79,844 shares during the period. JPMorgan Chase & Co. owned about 0.12% of Aclaris Therapeutics worth $219,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Commonwealth Equity Services LLC purchased a new position in Aclaris Therapeutics during the fourth quarter worth approximately $36,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Aclaris Therapeutics by 173.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 908,819 shares of the biotechnology company’s stock valued at $2,254,000 after acquiring an additional 576,413 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Aclaris Therapeutics during the 4th quarter worth $383,000. Charles Schwab Investment Management Inc. purchased a new stake in Aclaris Therapeutics during the 4th quarter worth $82,000. Finally, Peapod Lane Capital LLC acquired a new stake in Aclaris Therapeutics in the 4th quarter valued at $1,003,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $1.44 on Friday. The company has a market capitalization of $155.92 million, a price-to-earnings ratio of -2.77 and a beta of 0.42. Aclaris Therapeutics, Inc. has a one year low of $0.95 and a one year high of $5.17. The stock has a 50-day simple moving average of $1.48 and a 200 day simple moving average of $2.24.

Analysts Set New Price Targets

Several equities research analysts recently commented on ACRS shares. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating for the company. Finally, Scotiabank started coverage on shares of Aclaris Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.